PAHC as reported
Phibro Animal Health Corporation reported $1.50B of revenue over the trailing twelve months, +26% on the year before. 11 reported series are charted on this page, each one as filed.
$1.50B
Revenue, trailing twelve months · to Q3 2026 · +26% against the twelve months before
- Net Income
- $95M
Net Income · +200% year on year · trailing twelve months to Q3 2026
- Free Cash Flow
- $13M
Free Cash Flow · −74% year on year · trailing twelve months to Q3 2026
- Op Margin
- 12%
Op Margin · trailing twelve months to Q3 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $1.50B | +26% | Q3 2026 |
| Net Income | $95M | +200% | Q3 2026 |
| EPS | $2.34 | +200% | Q3 2026 |
| Gross Margin | 33% | n/a | Q3 2026 |
| Op Margin | 12% | n/a | Q3 2026 |
| Net Margin | 6.4% | n/a | Q3 2026 |
| ROE | 23% | n/a | Q3 2026 |
| ROA | 5.4% | n/a | Q3 2026 |
| ROIC | 14% | n/a | Q3 2026 |
| Free Cash Flow | $13M | −74% | Q3 2026 |
| P/E | 15.4 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Phibro Animal Health Corporation (PAHC) - Revenue & ProfitRevenue & ProfitPhibro Animal Health Corporation (PAHC)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #11 of 28 by Smart Score